About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 255  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size


 
EDITORIAL
Year : 2009  |  Volume : 2  |  Issue : 3  |  Page : 107 Table of Contents   

Gene therapy within our vision: Illustrating the genetic paradigm


Clinical Genetics, University of Nottingham, United Kingdom

Date of Web Publication28-Oct-2009

Correspondence Address:
Sandy Raeburn
Clinical Genetics, University of Nottingham
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-620X.57307

Rights and Permissions

How to cite this article:
Raeburn S. Gene therapy within our vision: Illustrating the genetic paradigm. Oman J Ophthalmol 2009;2:107

How to cite this URL:
Raeburn S. Gene therapy within our vision: Illustrating the genetic paradigm. Oman J Ophthalmol [serial online] 2009 [cited 2020 Jun 4];2:107. Available from: http://www.ojoonline.org/text.asp?2009/2/3/107/57307

Ophthalmology was one of the first medical specialties to be studied by genetic methods, which were described in a classic textbook. [1] The importance of the eye in genetics was emphasized further, when, in 1962, Arnold Sorsby became the first editor of the Journal of Medical Genetics. [2] The review of Gene Therapy in this issue, from the Narayana Nethralaya Postgraduate Institute of Ophthalmology in Bangalore, is timely. [3] It is useful to consider how specific gene therapy fits into the context of services for the diagnosis and management of genetic disorders, [4] with a focus on eye disease.

We could summarize three lessons: Firstly, investigation should start with precise history-taking (in the patient and family), which is followed by careful clinical examination (affected people as well as those apparently unaffected). Clinical testing and more specialized techniques such as imaging or DNA studies should always come later. This sequence is the only validated approach to genetic diagnosis, apart from screening in populations that are at higher risk. If specific therapy is anticipated, this paradigm is essential. Modern clinicians must not be tempted to take short cuts, e.g. by studying DNA in patients and relatives before the clinical features and the family history have been delineated in detail and have been recorded. Searching for some mutations without a clinical lead will generate confusing data and usually negative results. Unless there is a lucky selection, or a particular mutation is frequent in a population, such molecular 'fishing' will not clarify the genetic cause. The precise clinical diagnosis facilitates identification of the causative gene. The accurate family history shows up clinical heterogeneity and clarifies the mode of inheritance.

The second lesson is that symptoms and signs in other organs may underpin the correct diagnosis. Hospital services need clinical equipment for testing even more now than they did before the genetic revolution; the clinical physiology of all affected people, e.g., the nerve conduction velocity or the electroretinogram (ERG), will help to discriminate between some closely related syndromes.

Thirdly, other treatments must be considered, before resorting to gene therapy. This is because for the foreseeable future more visual problems will be prevented or treated globally by such methods, than by gene therapy.

Ophthalmologists can study rare disorders of the eye effectively by following the diagnostic approaches above and collaborating with molecular genetic researchers with special interests in the causative genes. The paradigm above is as robust in research as in clinical practice. Ophthalmologists will often encounter conditions, which are genetically heterogeneous. The interest there in helping the patient and family is great, but, in addition, the research rewards are excellent.

The most logical model for gene therapy is in treating single gene disorders. Good ophthalmology practice will reveal many more treatable single gene conditions like Leber's congenital amaurosis, which is the advance guard for other gene therapies. [5],[6]

 
   References Top

1.Sorsby A. Genetics in ophthalmology. London: Butterworth and Co. (Publishers) Ltd.; 1951.  Back to cited text no. 1      
2.Fraser Roberts JA. Obituary: Arnold Sorsby. J Med Genet 1980;17:410.  Back to cited text no. 2      
3.Uthra S, Kumaramanickavel G. Gene therapy in ophthalmology. Oman J Ophthalmol 2009;2:108-10.  Back to cited text no. 3    Medknow Journal  
4.Raeburn S. Genetic Services in the Sultanate of Oman and other Gulf Countries: Progress is needed now. Sultan Qaboos Univ Med J 2008;8:129-35.  Back to cited text no. 4      
5.Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  
6.Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's Congenital Amaurosis. N Engl J Med 2008;358:2240-8.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]  




 

Top
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed2049    
    Printed150    
    Emailed0    
    PDF Downloaded601    
    Comments [Add]    

Recommend this journal